Descripción del proyecto
Una nueva biopsia líquida de alta sensibilidad en el tratamiento del cáncer
El análisis de los biomarcadores del cáncer durante el seguimiento del tratamiento y en el período posoperatorio requiere una alta sensibilidad. El equipo del proyecto BiopSense, financiado con fondos europeos, está desarrollando una novedosa tecnología que permite detectar con gran sensibilidad el polimorfismo de un solo nucleótido en las muestras, lo que permite el cribado de cabecera de las biopsias líquidas. Esta plataforma de diagnóstico representará un sistema abierto que puede dar cabida al diseño de nuevos objetivos de diagnóstico. La tecnología se basa en un invento patentado e incluirá funciones para la preparación automatizada de muestras y el diseño de laboratorio en un chip. Los objetivos del proyecto incluyen la verificación de todos los componentes de la plataforma y el establecimiento de la sensibilidad y precisión de la química para evaluarla comparándola con una plataforma de espectrometría de masas de la competencia.
Objetivo
Extremely high sensitivity is needed for the detection of cancer biomarkers during the follow-up of the treatment or post-operation period. We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism from blood, enabling point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable customized follow-up of the cancer medication in local hospitals and health care centers. The technology is based on our invention (US patent allowed) further developed in the ERC CoG project, but will have features for automated sample preparation and lab-on-chip design, which need to be verified and combined in the complete platform. For pre-commercialization of the technology, the sensitivity and accuracy of the chemistry will be determined and compared against competing mass spectrometric platform (UltraSEEK by Agena), upgrading our technology from phase TRL 4 to TRL 5. Patent shield of the technology is extended and options for transferring IPR from the University are clarified. Results are presented in investor convention and oncology conferences, and negotiations with investors and out-licensors are started. Three international biotech companies take part in the steering group. The technology allows business potential in device and kit production, but especially in international service business for personalised panel components and medical consultation. The expected price of the device and sample prep will be 30-40% cheaper than that of the closest competitor, but even better it allows flexible design of personalized diagnostic panels. The development for boosting the innovation to market will continue either through a spin-out supported by international investors, together with partnering companies, or through out-licensing.
Ámbito científico
Programa(s)
Régimen de financiación
ERC-POC - Proof of Concept GrantInstitución de acogida
40100 Jyvaskyla
Finlandia